Literature DB >> 5285386

Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man.

D S Davies, S S Thorgeirsson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5285386     DOI: 10.1111/j.1749-6632.1971.tb46918.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  18 in total

Review 1.  General aspects on biotransformation and elimination of organic compounds in connection with occupational exposure.

Authors:  O Vesterberg
Journal:  Int Arch Occup Environ Health       Date:  1975-08-14       Impact factor: 3.015

2.  Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.

Authors:  G W Hepner; E S Vesell
Journal:  Am J Dig Dis       Date:  1975-01

3.  Antipyrine elimination in critically ill patients.

Authors:  L Mirvis; N Buchanan; C Eyberg
Journal:  Intensive Care Med       Date:  1979-05       Impact factor: 17.440

4.  The pharmacokinetics of acetanilide and of diphenylhydantoin sodium.

Authors:  J L Cunningham; M F Bullen; D A Evans
Journal:  Eur J Clin Pharmacol       Date:  1974-10-04       Impact factor: 2.953

5.  Immediate decrease by hydrocortisone of the plasma half-life of antipyrine.

Authors:  A Breckenridge; C W Burke; D S Davies; M L Orme
Journal:  Br J Pharmacol       Date:  1973-02       Impact factor: 8.739

6.  [Studies on the effect of uremia on phenylbutazone and aminophenazone metabolism in man].

Authors:  H W Leber; A Harders; G Schütterle
Journal:  Klin Wochenschr       Date:  1972-12-01

7.  Effect of rifampicin treatment on the metabolism of oestradiol and 17alpha-ethinyloestradiol by human liver microsomes.

Authors:  H M Bolt; H Kappus; M Bolt
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

8.  Liver function in physically trained subjects: galactose elimination capacity, plasma disappearance of indocyanine green, and aminopyrine metabolism in long-distance runners.

Authors:  J J Ducry; H Howald; T Zysset; J Bircher
Journal:  Dig Dis Sci       Date:  1979-03       Impact factor: 3.199

Review 9.  Clinical pharmacokinetics of phenylbutazone.

Authors:  J Aarbakke
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

10.  Acetanilide oxidation in phenylbutazone-associated hypoplastic anaemia.

Authors:  J L Cunningham; M J Leyland; I W Delamore; D A Evans
Journal:  Br Med J       Date:  1974-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.